Risk assessment should therefore focus on route, allergy history, skin conditions, wound status, immune status, medications, pregnancy, breastfeeding, and whether the product is cosmetic, compounded, or investigational [7], [8], [11]
Overall survival (OS) and disease-free survival (DFS), defined as the time from operation to death and recurrence, respectively, were used as surrogates of prognosis
This suggests that, despite errors caused by conversion, the total B12 contents by quantification using the cyanidation conversion method may still be within an acceptable range
Particularly relevant for implant patients over 45
Endocrine disruptors are not going away any time soon and are likely to increase in diversity and concentration in the future
Analysis of compounded peptide product quality and patient safety implications